Q2 FY26 Quarterly Activities Report and Appendix 4C
| Stock | VFY.ASX (VFY.ASX) |
|---|---|
| Release Time | 29 Jan 2026, 8:17 a.m. |
| Price Sensitive | Yes |
Vitrafy Life Sciences reports Q2 FY26 activities
- Entered strategic agreement with IMV Technologies for animal reproduction
- Launched first Guardion device in North America
- Continued U.S. military testing for blood platelets cryopreservation
- Ended quarter with $22.8m in cash and growing pipeline
Vitrafy Life Sciences Limited (ASX: VFY) reported its Quarterly Activities Report and Appendix 4C Cash Flow report for the second quarter ended 31 December 2025 (Q2) of Financial Year 2026 (FY2026). Key highlights include: Entering a strategic commercial agreement with global animal-assisted reproduction leader IMV Technologies, the arrival of the first Guardion device (formerly VCU2) in North America for commercial launch, chair succession to Dr Leigh Farrell and appointment of Independent Non-Executive Director Dr Jeannette Joughin, continued progress through U.S. Military phase II testing for cryopreservation of blood platelets, and finishing the quarter with $22.8m in cash and term deposits and a growing pipeline of demand for Vitrafy's new technology in blood and cell and gene market segments. The company also provided updates on its animal health, human health, and product development and commercial operations during the quarter.
The company estimates it has approximately 8 quarters of funding available based on the most recent quarter's net cash used in operating activities. Across the balance of FY26, average quarterly cash costs are expected to increase around 10-15% in the current half, coinciding with the company's investment in the ramp up of key regulatory testing work for medical device registration, expansion of the commercial team in the US and investment in an initial fleet of devices to meet anticipated demand.
Vitrafy will continue its commercialisation efforts on the human health market in North America, with a particular focus on the blood and cell and gene therapy sectors. The company will continue investing in the production of Guardion units for commercial deployment, in anticipation of expected demand within the blood and cell and gene therapy markets. Activities under the Agreement with IMV are expected to commence in February.